Combination of a T cell activating therapy and anti-phosphatidylserine enhances anti-tumour immune responses in a HPV16 E7-expressing C3 tumour model

DPX is a novel delivery platform that generates targeted CD8 (+) T cells and drives antigen-specific cytotoxic T cells into tumours. Cancer cells upregulate phosphatidylserine (PS) on the cell surface as a mechanism to induce an immunosuppressive microenvironment. Development of anti-PS targeting an...

Descripción completa

Detalles Bibliográficos
Autores principales: Dirk, Brennan S., Weir, Genevieve, Quinton, Tara, Hrytsenko, Olga, Stanford, Marianne M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904807/
https://www.ncbi.nlm.nih.gov/pubmed/33627686
http://dx.doi.org/10.1038/s41598-021-82108-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7904807/
https://www.ncbi.nlm.nih.gov/pubmed/33627686
http://dx.doi.org/10.1038/s41598-021-82108-4

Ejemplares similares